The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Anlotinib: a novel multi-targeting TKI treatment

lobbyist0724
lobbyist0724 CSN Member Posts: 521 Member
in Kidney Cancer #1

It is exciting to see more new treatments being available.

 

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.

https://www.urotoday.com/recent-abstracts/urologic-oncology/renal-cancer/106996-anlotinib-a-novel-multi-targeting-tyrosine-kinase-inhibitor-in-clinical-development.html

Like Care

Discussion Boards